#1 Clinical Trials Search in Europe

Dobutamine Hydrochloride

This article explores the use of Dobutamine Hydrochloride in various clinical trials. Dobutamine is a medication used to treat heart conditions and improve blood flow. The trials discussed here investigate its effects on different aspects of cardiovascular function, including hepatic blood flow, cardiac conduction, and treatment of sepsis and heart failure. We’ll examine how researchers are studying this drug to better understand its potential benefits and optimal usage in medical settings.

Table of Contents

What is Dobutamine?

Dobutamine hydrochloride, also known by the brand names Dobutrex and Simdax, is a medication used to treat certain heart conditions[1]. It belongs to a class of drugs called inotropes, which help improve the heart’s pumping ability[2].

Uses of Dobutamine

Dobutamine is primarily used in the following situations:

  • Heart failure: It helps improve heart function in patients with chronic heart failure[1].
  • Cardiogenic shock: This is a serious condition where the heart can’t pump enough blood to meet the body’s needs. Dobutamine can help improve blood flow in this situation[3].
  • After heart surgery: It’s often used to support heart function following cardiac surgery[2].
  • Stress tests: Dobutamine is used in certain heart stress tests to evaluate heart function[4].

How Dobutamine Works

Dobutamine works by stimulating receptors in the heart called beta-1 adrenergic receptors. This stimulation causes the heart to beat more strongly and quickly, increasing the amount of blood it pumps out with each beat. This effect is known as an “inotropic” effect[5].

In addition to its effects on the heart, dobutamine can also increase blood flow to other organs in the body, such as the liver and kidneys[5][1].

How Dobutamine is Administered

Dobutamine is typically given as an intravenous (IV) infusion in a hospital setting. The dose and duration of treatment can vary depending on the patient’s condition and response to the medication. Some common dosing regimens include:

  • Starting at 5 mcg/kg/min and increasing up to 20 mcg/kg/min[5]
  • A continuous infusion of 0.1 mcg/kg/min for 65 minutes after an initial loading dose[1]
  • Doses ranging from 3 to 6 mcg/kg/min[6]

Effects of Dobutamine

When administered, dobutamine can have several effects on the body:

  • Increased heart rate and strength of contractions: This leads to improved cardiac output (the amount of blood pumped by the heart)[5].
  • Improved blood flow to organs: Studies have shown that dobutamine can increase blood flow to the liver and kidneys[5][1].
  • Changes in blood pressure: Dobutamine can affect blood pressure, though the exact effect can vary depending on the patient’s condition[5].

Ongoing Research

Several clinical trials are currently investigating various aspects of dobutamine use:

  • Its effects on liver blood flow during surgery[5]
  • Its use in patients with sepsis (a severe infection affecting the whole body)[3]
  • Its effects on heart function in patients with metabolic syndrome and type 2 diabetes[7]
  • Its impact on kidney function in heart failure patients[1]

Potential Side Effects

While dobutamine can be very beneficial in certain situations, it can also have side effects. Some potential side effects include:

  • Rapid heart rate (tachycardia)[2]
  • Abnormal heart rhythms (arrhythmias)[2]
  • Chest pain[4]
  • Changes in blood pressure[5]

It’s important to note that dobutamine is typically used in hospital settings where patients can be closely monitored for these potential side effects.

Aspect Details
Primary Uses in Trials Improving hepatic blood flow, treating sepsis and hypoperfusion, assessing hypertrophic obstructive cardiomyopathy, evaluating cardiac conduction effects
Administration Method Intravenous infusion, typically 2-20 mcg/kg/min
Duration of Use Varies by trial, from a few hours to 48 hours or more
Potential Benefits Improved cardiac output, maintained organ perfusion, counteracting anesthetic effects
Potential Risks Increased heart rate, arrhythmias, blood pressure changes
Measurement Methods Echocardiography, hemodynamic monitoring, organ-specific blood flow assessment, clinical outcome evaluation
Comparison Studies Versus other drugs (e.g., levosimendan), liberal vs. restrictive use protocols

FAQ

  • What is Dobutamine Hydrochloride used for in clinical trials? Dobutamine Hydrochloride is being studied in clinical trials for various purposes, including improving hepatic blood flow during surgery, treating sepsis and hypoperfusion, assessing hypertrophic obstructive cardiomyopathy, evaluating effects on cardiac conduction, and comparing its efficacy to other drugs in treating heart failure and cardiorenal syndrome.
  • How is Dobutamine administered in these trials? In the trials, Dobutamine is typically administered intravenously. The dosage and duration vary depending on the study, ranging from 2-20 mcg/kg/min for periods of a few hours up to 48 hours or more, depending on the specific trial protocol and patient condition.
  • What are some potential benefits of using Dobutamine in cardiac surgery? Dobutamine may help maintain adequate blood flow to organs during surgery, counteract the depressant effects of anesthetics on the heart, and improve cardiac output. Some trials are investigating whether it can help reduce complications and improve outcomes in cardiac surgery patients.
  • Are there any risks or side effects associated with Dobutamine use in these trials? While the trials are still ongoing, known potential side effects of Dobutamine include increased heart rate, arrhythmias, and changes in blood pressure. Some studies are specifically looking at whether more restrictive use of Dobutamine can reduce adverse events while maintaining its benefits.
  • How do researchers measure the effects of Dobutamine in these trials? Researchers use various methods to measure Dobutamine's effects, including echocardiography to assess cardiac function and blood flow, monitoring of hemodynamic parameters like blood pressure and cardiac output, measurement of organ-specific blood flow (e.g., hepatic blood flow), and assessment of clinical outcomes such as mortality rates and complication incidence.

Ongoing Clinical Trials on Dobutamine Hydrochloride

  • Study on Isoflurane, Propofol, and Dobutamine Hydrochloride for Sedation in Adults with Severe Cardiogenic Shock on ECMO

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study Comparing Serratus Plane Block, Capsaicin, and Botulinum Toxin Type A for Chronic Pain in Post-Mastectomy Patients

    Recruiting

    2 1 1 1
    Investigated drugs:
    France

  • Study of dexmedetomidine and a drug combination for treating patients on mechanical ventilation with septic shock.

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Evaluation of opioid use with nociceptive monitoring in intensive care patients receiving deep sedation with isoflurane, propofol, and midazolam

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Spain

  • Study on Sedation Safety and Effectiveness in Bronchoscopy: Comparing Propofol/Pethidine and Midazolam/Pethidine for Patients with Respiratory Conditions

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Italy

  • Study on the Effects of Dobutamine and Levosimendan in Patients with Heart Failure and Reduced Left Ventricular Function

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Spain

  • Study on Midazolam and Morphine for Symptom Relief in Elderly Patients at End of Life

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Belgium

  • Study on the Safety and Effects of TNG908 in Patients with Advanced or Metastatic Solid Tumors Missing the MTAP Gene

    Not recruiting

    2 1 1 1
    Investigated drugs:
    France

  • Study on the Effectiveness and Safety of Chloroprocaine Hydrochloride for Children Undergoing Flat Foot or Inguinal Hernia Surgery

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study Comparing Aficamten and Metoprolol for Adults with Symptomatic Hypertrophic Cardiomyopathy

    Not recruiting

    3 1 1
    Investigated drugs:
    Denmark France Germany Hungary Italy The Netherlands +1

Glossary

  • Dobutamine Hydrochloride: A medication used to treat heart conditions by increasing the strength and efficiency of heart contractions. It's often used in emergency situations or during surgery to improve blood flow and heart function.
  • Hemodynamic: Relating to the flow of blood within the organs and tissues of the body. Hemodynamic measurements help assess how well the heart is pumping and blood is flowing.
  • Cardiac output: The amount of blood the heart pumps through the circulatory system in one minute. It's an important measure of heart function.
  • Echocardiography: An imaging technique that uses sound waves to create pictures of the heart, allowing doctors to see its size, structure, and how well it's functioning.
  • Inotropic agent: A substance that changes the force of heart muscle contractions. Dobutamine is a positive inotrope, meaning it increases the strength of heart contractions.
  • Sepsis: A life-threatening condition that occurs when the body's response to infection causes widespread inflammation and organ dysfunction.
  • Cardiorenal syndrome: A condition where heart failure leads to kidney dysfunction, or vice versa, creating a cycle of worsening heart and kidney problems.
  • Hypertrophic obstructive cardiomyopathy: A heart condition where the heart muscle becomes abnormally thick, making it harder for the heart to pump blood effectively.
  • Transesophageal echocardiography (TEE): A type of echocardiogram where the ultrasound probe is passed into the esophagus to obtain clearer images of the heart.
  • Glomerular filtration rate (GFR): A measure of how well the kidneys are filtering waste from the blood, used to assess kidney function.

References

  1. https://clinicaltrials.gov/study/NCT02133105
  2. https://clinicaltrials.gov/study/NCT02361801
  3. https://clinicaltrials.gov/study/NCT05953142
  4. https://clinicaltrials.gov/study/NCT05025644
  5. https://clinicaltrials.gov/study/NCT04893655
  6. https://clinicaltrials.gov/study/NCT06210217
  7. https://clinicaltrials.gov/study/NCT02505451